Herpes simplex virus vaccine
AssigneeGenVec, Inc.
InventorsLisa Wei, Douglas E. Brough, Christopher Lazarski
Life of this patent
Estimating the term…
Abstract
Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
Claims21
-66. (canceled)
A method of determining efficacy of an antiviral agent against HSV in a rodent model, comprising administering HSV to a female rodent by intravaginal inoculation, administering the antiviral agent to the female rodent, and evaluating symptoms of HSV infection in the rodent model to determine efficacy of the antiviral agent.
A method of determining efficacy of an antiviral agent against HSV in a neonatal guinea pig model, comprising administering HSV to the neonatal guinea pig by intranasal inoculation, administering the antiviral agent to the neonatal guinea pig, and evaluating symptoms of HSV infection in the neonatal guinea pig model to determine efficacy of the antiviral agent.
Dependencies are inferred from the claim text.